Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Gattermeyer-Kell, L; Khalil, M; Kern, D; Franthal, S; Katschnig-Winter, P; Kögl, M; Demjaha, R; Tafrali, C; Hofer, E; Schmidt, R; Enzinger, C; Schwingenschuh, P.
Serum glial fibrillary acidic protein is elevated in early-stage late-onset essential tremor and associated with tremor progression.
J Neural Transm (Vienna). 2025; Doi: 10.1007/s00702-025-02970-8
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Gattermeyer-Kell Lukas
Schwingenschuh Petra
Co-Autor*innen der Med Uni Graz
Demjaha Rina
Enzinger Christian
Franthal Sebastian Othmar
Hofer Edith
Katschnig-Winter Petra
Kern Daniela
Khalil Michael
Kögl Mariella Waltraud
Schmidt Reinhold
Tafrali Cansu
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The role of neurodegeneration in essential tremor (ET) remains debated, particularly in patients with late disease onset. Neuropathological studies have identified structural changes in the Purkinje cells and its connections. Recent studies additionally suggested a role of cerebellar astrocytes. Increased levels of serum glial fibrillary acidic protein (sGFAP), an astrocytic intermediate filament, were found in various neuroinflammatory and neurodegenerative diseases. The objective of this case-control study was to investigate the role of sGFAP in ET focusing on early-stage late-onset patients. sGFAP was quantified by single molecule array at baseline and follow-up in 36 ET-patients (median follow-up period 5.3 years) and 36 age-matched healthy controls (4.9 years). ET-patients were assessed both at baseline and follow-up using the Fahn-Tolosa-Marin-Tremor-Rating-Scale. The ET group was stratified (1) by median age at onset and median disease duration in early-stage late-onset and early-onset/late-stage ET, and (2) by median sGFAP-level at baseline. Early-stage late-onset ET-patients had higher baseline-sGFAP than controls (p = 0.023) and higher follow-up-sGFAP and annual sGFAP-increase than both controls (p = 0.023; p = 0.007) and early-onset/late-stage ET-patients (p = 0.021; p = 0.024). Baseline sGFAP-level correlated with tremor severity at follow-up in the early-stage late-onset (rs = 0.704, p = 0.011) but not in the early-onset/late-stage group. Patients with high compared to low sGFAP-baseline levels had later disease onset (p < 0.001) and sGFAP-increase was associated to tremor progression only in high sGFAP-patients (p = 0.041). ET-plus and pure-ET-patients did not differ in any of the sGFAP-parameters. sGFAP is elevated in early stages of late-onset ET and associated to tremor progression, substantiating the role of a neurodegenerative process in ET in this subgroup.

Find related publications in this database (Keywords)
Essential tremor
Tremor
Serum glial fibrillary acidic protein
GFAP
Biomarker
© Med Uni Graz • Impressum